Idera Pharmaceuticals Profile

Performance

   

Odds of Distress

55%55%
Check how we calculate scores
Equity ratings for Idera Pharmaceuticals are calculated based on Macroaxis scoring framework. The performance scores are derived for the period starting July 16, 2019 and ending today October 14, 2019. Click here to learn more.

Idera Pharmaceuticals Profile

Idera Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for oncology in the United States. The company was founded in 1989 and is based in Exton, Pennsylvania. Idera Pharmaceuticals operates under Biotechnology classification in USA and is traded on BATS Exchange. It employs 36 people. more
Idera Pharmaceuticals Fama & French Pharmaceutical Products
Pharmaceutical Products
Fama & French Classification
Idera Pharmaceuticals SEC Filings
Idera Pharmaceuticals SEC Filings
Security & Exchange Commission EDGAR ReportsView All
NameIdera Pharmaceuticals
CEO and President and DirectorVincent MilanoView All
Analyst Consensus
Piotroski F Score
Macroaxis Advice
Specialization
Healthcare, Biotechnology
InstrumentUSA Stock View All
RegionNorth America
LocationMassachusetts U.S.A
Business Address505 Eagleview Blvd., Suite 212, Exton, PA 19341, United States
ExchangeBATS Exchange
CIK Number0000861838
CUSIP44860M801
SectorHealthcare
IndustryBiotechnology
BenchmarkDOW
Websitewww.iderapharma.com
Phone484 348 1600
CurrencyUSD - US Dollar
Next Fiscal Year EndDecember 31, 2020
Most Recent QuarterJune 30, 2019
Last Fiscal Year EndDecember 31, 2018
Date Short InterestAugust 15, 2019
Idera Pharmaceuticals (IDRA) is traded on BATS Exchange in USA. It is located in 505 Eagleview Blvd., Suite 212, Exton, PA 19341, United States and employs 36 people. Idera Pharmaceuticals is listed under Pharmaceutical Products category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with current market capitalization of 84.51 M. Idera Pharmaceuticals conducts business under Healthcare sector and is part of Biotechnology industry. The entity has 28.84 M outstanding shares of which 826.22 K shares are currently shorted by private and institutional investors with about 4.23 trading days to cover. IDERA PHARMACEUTI currently holds about 52.37 M in cash with (46.59 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.82.
Check Idera Pharmaceuticals Probability Of Bankruptcy

Ownership Allocation (%)

Idera Pharmaceuticals Target Price Odds Analysis

Odds Below 2.56HorizonTargetOdds Above 2.56
45.04%30 days 2.56 54.81%
Based on normal probability distribution, the odds of Idera Pharmaceuticals to move above current price in 30 days from now is about 54.81 (This Idera Pharmaceuticals probability density function shows the probability of Idera Pharmaceuticals Stock to fall within a particular range of prices over 30 days) .

Idera Pharmaceuticals Top Holders

Idera Pharmaceuticals Major Institutional Holders

InstituionSecurity TypeTotal SharesValue
Lau Associates LlcCommon Shares10.2 K30 K
Baker Bros Advisors LpCommon Shares4.6 M12.3 M
View Idera Pharmaceuticals Diagnostics

Idera Pharmaceuticals Income Statement Over Time

Consolidated Income    Earning Before Interest and Taxes EBIT    Net Income    

Idera Pharmaceuticals Key Fundamentals

Idera Pharmaceuticals Against Markets

Did you try this?

Run Competition Analyzer Now

   

Competition Analyzer

Analyze and compare many basic indicators for a group of related or unrelated entities
All  Next Launch Module

Idera Pharmaceuticals Upcoming and Recent Events

Idera Pharmaceuticals Company Earnings Announcements Dates

Upcoming Quarterly Earning ReportNovember 5, 2019
Next Earnings ReportMarch 4, 2020
Next Fiscal Quarter EndSeptember 30, 2019
Next Fiscal Year EndMarch 4, 2020
Last Quarter Report DateJune 30, 2019
Last Earning Anouncement DateSeptember 30, 2018

Idera Pharmaceuticals Corporate Filings

Idera Pharmaceuticals Corporate Filings

Unclassified Corporate Event
Financial Statements and Exhibits. Regulation FD Disclosure. Entry into a Material Definitive Agreement
Regulation FD Disclosure
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Idera Pharmaceuticals Corporate Directors

Howard Pien Director
Kelvin Neu Director
Cristina Csimma Director
Please also check Risk vs Return Analysis. Please also try Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.
Search macroaxis.com